Improved Quality of Life in Patients with Psoriasis Receiving Apremilast: Real-World Data from the Netherlands

[1] Parisi R(2020)National, regional, and worldwide epidemiology of psoriasis: systematic analysis and modelling study BMJ 369 871-881

[2] Iskandar IYK(2014)Patient perspectives in the management of psoriasis: results from the population-based Multinational Assessment of Psoriasis and Psoriatic Arthritis Survey J Am Acad Dermatol 70 147-151

[3] Kontopantelis E(2010)Co-morbidity and age-related prevalence of psoriasis: analysis of health insurance data in Germany Acta Derm Venereol 90 adv00020-23

[4] Augustin M(2020)Psoriasis and mental health workshop report: exploring the links between psychosocial factors, psoriasis, neuroinflammation and cardiovascular disease risk Acta Derm Venereol 100 ii18-65.e19

[5] Griffiths CEM(2005)Psoriasis: epidemiology, clinical features, and quality of life Ann Rheum Dis 64 251-303

[6] Ashcroft DM(2019)Prevalence of psoriatic arthritis in patients with psoriasis: a systematic review and meta-analysis of observational and clinical studies J Am Acad Dermatol 80 299-10

[7] Lebwohl MG(2012)Living with psoriasis: prevalence of shame, anger, worry, and problems in daily activities and social life Acta Derm Venereol 92 1-1179

[8] Bachelez H(2011)Definition of treatment goals for moderate to severe psoriasis: a European consensus Arch Dermatol Res 303 1173-386

[9] Barker J(2018)Real-world data on the efficacy and safety of apremilast in patients with moderate-to-severe plaque psoriasis J Eur Acad Dermatol Venereol 23 383-57

[10] Augustin M(2019)Real-world data on the efficacy and safety of apremilast in Japanese patients with plaque psoriasis J Dermatolog Treat 30 51-2829

[1] Parisi R(2020)National, regional, and worldwide epidemiology of psoriasis: systematic analysis and modelling study BMJ 369 871-881

[2] Iskandar IYK(2014)Patient perspectives in the management of psoriasis: results from the population-based Multinational Assessment of Psoriasis and Psoriatic Arthritis Survey J Am Acad Dermatol 70 147-151

[3] Kontopantelis E(2010)Co-morbidity and age-related prevalence of psoriasis: analysis of health insurance data in Germany Acta Derm Venereol 90 adv00020-23

[4] Augustin M(2020)Psoriasis and mental health workshop report: exploring the links between psychosocial factors, psoriasis, neuroinflammation and cardiovascular disease risk Acta Derm Venereol 100 ii18-65.e19

[5] Griffiths CEM(2005)Psoriasis: epidemiology, clinical features, and quality of life Ann Rheum Dis 64 251-303

[6] Ashcroft DM(2019)Prevalence of psoriatic arthritis in patients with psoriasis: a systematic review and meta-analysis of observational and clinical studies J Am Acad Dermatol 80 299-10

[7] Lebwohl MG(2012)Living with psoriasis: prevalence of shame, anger, worry, and problems in daily activities and social life Acta Derm Venereol 92 1-1179

[8] Bachelez H(2011)Definition of treatment goals for moderate to severe psoriasis: a European consensus Arch Dermatol Res 303 1173-386

[9] Barker J(2018)Real-world data on the efficacy and safety of apremilast in patients with moderate-to-severe plaque psoriasis J Eur Acad Dermatol Venereol 23 383-57

[10] Augustin M(2019)Real-world data on the efficacy and safety of apremilast in Japanese patients with plaque psoriasis J Dermatolog Treat 30 51-2829